

# APPLY ANYWHERE ON AFFECTED SKIN OF PATIENTS WITH MILD TO MODERATE ATOPIC DERMATITIS<sup>1</sup>

Not for ophthalmic, oral, or intravaginal use.

EUCRISA is the **first and only** topical PDE-4 inhibitor for topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older.\*

**NOW AVAILABLE**

## PHOTOS FROM THE PIVOTAL TRIALS DEPICTING SUCCESS IN ISGA SCORE AT DAY 29<sup>2</sup>



- **Significantly more EUCRISA patients (31.4%) achieved success in ISGA** v(a score of Clear [0] or Almost Clear [1] with at least a 2-grade improvement from baseline) vs. vehicle (18%) at Day 29 ( $p < 0.001$ )<sup>†</sup>
- **48.5% of EUCRISA patients achieved an ISGA of Clear (0) or Almost Clear (1)** vs. 29.7% of vehicle patients at Day 29 ( $p < 0.001$ ; 2<sup>o</sup> endpoint)<sup>†</sup>

Actual case, individual results may vary. May not be representative of results in the general population.

### Indication and clinical use

- EUCRISA (crisaborole ointment, 2% w/w) is indicated for topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older

### Relevant warnings and precautions

- Hypersensitivity reactions, including contact urticaria
- Use in pregnant and nursing women
- Use in geriatric patients

PDE-4=phosphodiesterase-4.

\* Comparative clinical significance has not been established.

† Results from a multicenter, randomized, double-blind, parallel-group, vehicle-controlled trial of patients aged 2 to 79 years of age (mean age was 12.6 in the EUCRISA group and 11.8 in the vehicle group) with a 5% to 95% treatable body surface area (baseline mean was 17.9% in the EUCRISA group and 17.7% in the vehicle group). Patients were randomized 2:1 to receive EUCRISA (n=513) or vehicle (n=250) applied twice daily for 28 days.

References: 1. EUCRISA Product Monograph, June 11, 2018. 2. Paller A, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. JAAD 2016;75(3):494-503.

### For more information

Please consult the Product Monograph at <http://pfizer.ca/pm/en/Eucrisa.pdf> for important information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece.

The Product Monograph is also available by calling 1-800-463-6001.